PMID- 27209101
OWN - NLM
STAT- MEDLINE
DCOM- 20171024
LR  - 20220311
IS  - 1876-7591 (Electronic)
IS  - 1876-7591 (Linking)
VI  - 9
IP  - 6
DP  - 2016 Jun
TI  - LGE Provides Incremental Prognostic Information Over Serum Biomarkers in 
      AL Cardiac Amyloidosis.
PG  - 680-6
LID - S1936-878X(16)30191-7 [pii]
LID - 10.1016/j.jcmg.2015.10.027 [doi]
AB  - OBJECTIVES: This study sought to determine the prognostic value of cardiac 
      magnetic resonance (CMR) late gadolinium enhancement (LGE) in amyloid light chain 
      (AL) cardiac amyloidosis. BACKGROUND: Cardiac involvement is the major 
      determinant of mortality in AL amyloidosis. CMR LGE is a marker of amyloid 
      infiltration of the myocardium. The purpose of this study was to evaluate 
      retrospectively the prognostic value of CMR LGE for determining all-cause 
      mortality in AL amyloidosis and to compare the prognostic power with the 
      biomarker stage. METHODS: Seventy-six patients with histologically proven AL 
      amyloidosis underwent CMR LGE imaging. LGE was categorized as global, focal 
      patchy, or none. Global LGE was considered present if it was visualized on LGE 
      images or if the myocardium nulled before the blood pool on a cine multiple 
      inversion time (TI) sequence. CMR morphologic and functional evaluation, 
      echocardiographic diastolic evaluation, and cardiac biomarker staging were also 
      performed. Subjects' charts were reviewed for all-cause mortality. Cox 
      proportional hazards analysis was used to evaluate survival in univariate and 
      multivariate analysis. RESULTS: There were 40 deaths, and the median study 
      follow-up period was 34.4 months. Global LGE was associated with all-cause 
      mortality in univariate analysis (hazard ratio = 2.93; p < 0.001). In 
      multivariate modeling with biomarker stage, global LGE remained prognostic 
      (hazard ratio = 2.43; p = 0.01). CONCLUSIONS: Diffuse LGE provides incremental 
      prognosis over cardiac biomarker stage in patients with AL cardiac amyloidosis.
CI  - Copyright (c) 2016 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Boynton, Samuel J
AU  - Boynton SJ
AD  - Department of Radiology, Mayo Clinic Rochester, Rochester, Minnesota.
FAU - Geske, Jeffrey B
AU  - Geske JB
AD  - Department of Medicine, Division of Cardiovascular Diseases, Mayo Clinic 
      Rochester, Rochester, Minnesota.
FAU - Dispenzieri, Angela
AU  - Dispenzieri A
AD  - Department of Medicine, Division of Hematology, Mayo Clinic Rochester, Rochester, 
      Minnesota.
FAU - Syed, Imran S
AU  - Syed IS
AD  - Department of Medicine, Division of Cardiovascular Diseases, Mayo Clinic 
      Rochester, Rochester, Minnesota.
FAU - Hanson, Theodore J
AU  - Hanson TJ
AD  - Department of Radiology, Mayo Clinic Rochester, Rochester, Minnesota.
FAU - Grogan, Martha
AU  - Grogan M
AD  - Department of Medicine, Division of Cardiovascular Diseases, Mayo Clinic 
      Rochester, Rochester, Minnesota.
FAU - Araoz, Philip A
AU  - Araoz PA
AD  - Department of Radiology, Mayo Clinic Rochester, Rochester, Minnesota. Electronic 
      address: paraoz@mayo.edu.
LA  - eng
GR  - UL1 TR000135/TR/NCATS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20160518
PL  - United States
TA  - JACC Cardiovasc Imaging
JT  - JACC. Cardiovascular imaging
JID - 101467978
RN  - 0 (Biomarkers)
RN  - 0 (Contrast Media)
RN  - 0 (Immunoglobulin Light Chains)
RN  - 84F6U3J2R6 (gadodiamide)
RN  - K2I13DR72L (Gadolinium DTPA)
SB  - IM
CIN - JACC Cardiovasc Imaging. 2016 Jun;9(6):687-9. PMID: 27209102
MH  - Aged
MH  - Amyloidosis/blood/*diagnostic imaging/immunology/mortality
MH  - Biomarkers/blood
MH  - Cardiomyopathies/blood/*diagnostic imaging/immunology/mortality
MH  - Chi-Square Distribution
MH  - Contrast Media/*administration & dosage
MH  - Female
MH  - Gadolinium DTPA/*administration & dosage
MH  - Humans
MH  - Immunoglobulin Light Chains
MH  - Kaplan-Meier Estimate
MH  - *Magnetic Resonance Imaging, Cine
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
OTO - NOTNLM
OT  - amyloidosis
OT  - enhancement
OT  - magnetic resonance imaging
OT  - outcomes
OT  - prognosis
EDAT- 2016/05/23 06:00
MHDA- 2017/10/25 06:00
CRDT- 2016/05/23 06:00
PHST- 2015/02/23 00:00 [received]
PHST- 2015/10/16 00:00 [revised]
PHST- 2015/10/21 00:00 [accepted]
PHST- 2016/05/23 06:00 [entrez]
PHST- 2016/05/23 06:00 [pubmed]
PHST- 2017/10/25 06:00 [medline]
AID - S1936-878X(16)30191-7 [pii]
AID - 10.1016/j.jcmg.2015.10.027 [doi]
PST - ppublish
SO  - JACC Cardiovasc Imaging. 2016 Jun;9(6):680-6. doi: 10.1016/j.jcmg.2015.10.027. 
      Epub 2016 May 18.